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Abstract  
Objectives. We elucidated pathophysiology of pediatric gallstone disease by assessing liver 
expression of bile transporters in relation to bile acids and surrogates of cholesterol absorption 
and synthesis in serum and gallstones. 
Methods. RNA expression of canalicular bile transporters in liver biopsies from 32 pediatric 
gallstone patients and from six liver donors (controls) was measured by qRT-PCR. 
Concentrations of cholesterol and precursors, plant sterols and bile acids in gallstones, and in 
serum of the patients and 82 healthy children were measured.  Primary outcomes were the 
difference in RNA expressions and serum sterol profiles between patients and controls.  
Results. Cholesterol stones (CS; n=15) contained cholesterol >42% and pigment stones (PS; 
n=17) <9% of weight. CS-patients had markedly lower serum plant sterols (absorption) and 
higher cholesterol precursors (synthesis) than PS-patients or healthy controls. CS contained 
several times more cholesterol precursors and less plant sterols relative to cholesterol than PS, 
which were enriched by primary bile acids (12-5.2 fold, p<0.001). Liver RNA expression of 
ABCG5/G8 was similarly increased 2.5-1.8 fold (p<0.002) in CS and PS-patients, while PS-
patients had higher ABCB11 expression (p<0.05). In PS bile acid concentration correlated with 
gallstone plant sterols (R2 = 0.83, p<0.0001), and ABCG5 expression with ACBC11 expression 
(R2 = 0.27, p = 0.03). 
Conclusions. In CS, upregulation of ABCG5/G8 expression associates with low absorption and 
high gallstone content of cholesterol. In PS, activation of bile acid transport by ACBC11 
interconnects with hepatic upregulation of ABCG5/G8 enriching PS with bile acids and plant 
sterols.    
Keywords: Plant sterols, bile acids, RNA expression  
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What is new? 
• Gallstone formation in children is related with increased hepatic expression of 
hepatocyte sterol transporter ABCG5/G8 
• Cholesterol stones (CS) are associated with decreased absorption and increased 
synthesis and biliary secretion of cholesterol and its precursors 
• In pigment gallstones (PS) activation of bile acid transport by ABC11 interconnects with 
hepatic upregulation of ABCG5/G8 enriching PS with bile acids and plant sterols 
What is known? 
• The incidence of pediatric gallstone disease is increasing 
• In children PS are as common as CS   
• Gallstone formation is related with altered cholesterol metabolism 
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Introduction  
Pediatric gallstone disease and cholecystectomy rate are increasing in western world for unclear 
reasons (1). In adults, cholesterol stones (CS) are by far the most common gallstone type known 
to associate with biliary hypersecretion of cholesterol, obesity and features of metabolic 
syndrome such as decreased insulin sensitivity and liver steatosis (2,3,4). The risk factors for 
pediatric gallstones are less clearly defined (5,6). Contrary to adults, pigment stones (PS) form a 
significant proportion of gallstones in children (7,8). PS are composed mostly of calcium 
bilirubinate and often associate with variable underlying conditions such as hemolysis, portal 
hypertension, inflammatory bowel disease and ileal dysfunction (6, 8, 9, 10, 11).  
Alterations in the cholesterol metabolism and supersaturation of bile with cholesterol over 
phospholipids and bile acids, are closely related with development of CS (4, 12). Serum plant 
sterols are surrogates for intestinal cholesterol absorption (13), whereas serum cholesterol 
precursors mirror the whole body cholesterol synthesis (13, 14, 15). Studies in both adults and 
children have demonstrated that CS associate with decreased intestinal cholesterol absorption as 
measured by low serum plant sterols (7, 8, 12), while enhanced biliary secretion in patients with 
CS is reflected by the accumulation of  cholesterol and plant sterols into bile (12) and gallstones 
(8). By definition, PS have considerably lower cholesterol concentration, and weaker connections 
to cholesterol metabolism than CS (5, 8). Despite normal intestinal cholesterol absorption, 
children with PS showed increased serum surrogates of cholesterol synthesis and high gallstone 
bile acid content (7), which could be attributable to increased biliary secretion of bile acids by 
canalicular bile acid transporter ABCB11. 
ATP-binding cassette (ABC) transporters ABCG5 and ABCG8 not only transport absorbed 
cholesterol and plant sterols from enterocytes back to the intestinal lumen, but also from 
hepatocytes to the bile canaliculus. Accordingly, enhanced function of ABCG5/8 in the liver and 
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the intestine should lead to increased secretion of cholesterol and plant sterols into bile as well as 
back into the intestinal lumen and decreased intestinal absorption. Indeed, a recent study showed 
that a gain-of-function genetic variant D19H of ABCG8 predisposes to gallstones in humans (16), 
and a meta-analysis of genome-wide association studies identified four gene loci for ABCG8 as 
susceptibility loci for gallstone disease (17,18). In adult gallstone patients, up-regulated hepatic 
expression of ABCG5/8 has been associated with cholesterol supersaturation of bile (19). 
Whether similar up-regulation of ABCG5/8 is actually present in pediatric gallstone patients and 
whether there are differences in bile transporter expression between CS and PS remains 
unknown. 
In the present comparative cross-sectional study, we aimed to explore the roles of canalicular 
sterol, phospholipid, bile acid and bilirubin transporters in pathophysiology of pediatric gallstone 
disease. For this, we measured hepatic RNA expression of the transporters and their nuclear 
receptor upstream regulators liver x receptor (LXR) and farnesoid X receptor (FXR), and assessed 
their relation to serum and gallstone cholesterol, cholesterol precursors, plant sterols and bile 
acids. We hypothesized that ABCG5/8 expression is upregulated in patients with CS, whereas 
bile acid secretion would associate with development of PS. 
Patients and Methods 
Ethics  
The institutional ethical committee approved the study (&27/2010, 434/13/03/2008). An 
informed consent was obtained from patients and controls and/or their caregivers before any 
experimental procedures. 
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Patients and controls 
From 1994 to 2014 we performed cholecystectomy for 80 pediatric patients with 
cholecystolithiasis (1994-2003 n=21, 2004-2014 n=59). Thirty-two consecutive pediatric patients 
with median age 13 (10-16) years, who underwent cholecystectomy for symptomatic gallstones 
from March 2009 to January 2014 were enrolled.  Control liver specimens were obtained from 
transplant donor livers (n=6) with median age 23 (range 11- 42) years (p=0.004 vs patients) and 
control serum samples were withdrawn from generally healthy day-surgery patients (n=82) with 
median age 8.9 (4.1-16) years (p=0.05 vs patients) without known gastrointestinal, hepatobiliary, 
endocrine or lipid metabolism disorders. (Suppl Figure 1, Supplemental Digital Content, 
http://links.lww.com/MPG/B642)  
Study procedures 
Fasting serum samples and liver biopsies were obtained at the time of cholecystectomy. 
Gallstones were retrieved from the removed gallbladder (n = 31), or during endoscopic 
sphincterotomy (n = 1). During cholecystectomy two 23 mm core needle biopsies were obtained 
under laparoscopic control from the right liver lobe.  
Serum total cholesterol, high-density lipoprotein (HDL) and low-density lipoprotein (LDL) 
cholesterol and serum triglycerides were analyzed enzymatically. Our hospital laboratory 
analyzed routine liver biochemistries, including alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), alkaline phosphatase (AFOS) glutamyl transferase (GT), bilirubin, 
conjugated bilirubin, bile acids and prealbumin. Classification of the gallstones into CS and PS 
was performed as described earlier (2, 10). 
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Analyses of non-cholesterol sterols in serum and gallstones  
Serum and liver samples were snap frozen and stored at -20°C, and gallstones were dried and 
stored in room temperature until analyzed. Serum and gallstone cholesterol, cholesterol 
precursors (cholestenol, lathosterol and desmosterol), cholestanol and plant sterols (campesterol, 
sitosterol, stigmasterol and avenasterol) and gallstone bile acids (chenodeoxyocholic, lithocholic, 
ursodeoxycholic, cholic and deoxycholic acid) were measured as trimethylsilylethers from 
nonsaponifiable material by capillary gas-liquid chromatography with flame ionization detection 
and using 50-m nonpolar capillary columns (Ultra 1 and Ultra 2, Agilent Technologies, Palo 
Alto, California), with 5α-cholestane as an internal standard as described in detail previously 
(20). The non-cholesterol sterols were expressed as ratio to the cholesterol concentration of the 
same gas-liquid chromatography run (100 x µg/mg of cholesterol), and bile acids as µg/100mg of 
stone. We calculated the ratios lathosterol/sitosterol and lathosterol/cholestanol, for biomarkers 
of whole-body cholesterol metabolism (13, 21) and campesterol/cholestanol for a biomarker of 
dietary plant sterol intake. (22)  
Liver and gallbladder histology 
Liver and gallbladder specimens were fixed in formalin, embedded in paraffin, sliced, and 
stained with hematoxylin and eosin, reticulin, herovici, Pearl´s iron, Periodic acid-Schiff´s, and 
cytokeratin-7. 
RNA isolation and expression analysis 
Liver tissue specimens were embedded in RNAlater-solution (Ambion, Life technologies, 
Thermo Fisher Scientific Inc., Waltham, MA, USA) and frozen until analyzed. RNA was 
extracted with the RNAeasy Mini Kit (QIAGEN, Frederick, Maryland, USA) and RNA integrity 
was assessed spectrophotometrically. RNA expression (LXR, FXR, ABCG5, ABCG8, ABCB4, 
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ABCB11 and ABCC2) was analyzed in triplicate by quantitative real-time polymerase chain 
reaction using PCR Array (QIAGEN SA Biosciences, Frederick, Maryland, USA) on an ABI 
7700 Sequence Detection System (Perkin-Elmer Life Sciences, Boston, MA, USA) according to 
the manufacturer’s instructions. Quantification of target gene mRNA expression was performed 
using the ΔΔCt method and expressed as fold change after normalization to housekeeping genes 
and relative to control subjects. 
Statistical analyses 
In order to ascertain adequate size of the study groups 2-sided power analysis calculation was 
performed for statistical power of 0.80, p=0.05. The study groups were of adequate size for the 
comparison of stone concentrations of sterols and bile acids between CS and PS and for the 
comparison of the most important serum sterol concentrations between patients and controls. In 
the comparison of RNA expressions we assumed that 1.5 vs 1.0 fold difference (SD 0.3 fold) was 
significant. Power calculations indicated adequate size of the study cohorts, small cohort size 
(patients n=32, controls n=6) reduced reliability of the calculations. 
Unless otherwise stated, data are expressed as medians (interquartile range) or means (95% 
confidence interval). Multiple comparisons between groups were performed with Kruskal Wallis 
Test. If the group effect was significant in multiple comparisons, post hoc pairwise comparisons 
were performed with Mann Whitney U test. Fisher’s exact was used to compare frequencies of 
categorical variables, and Spearman rank correlation test to assess linear relationships between 
variables. A p-value less than 0.05 was considered statistically significant. 
Results  
Patients and controls 
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The gender distribution was comparable between patients (females 19/32, 59%) and controls 
(females 40/88, 45%, p=0.22). Median Iso-BMI was 23 (19-27) kg/m2 in patients and 23 (20-
25) kg/m2 in controls (p=0.89). Liver biochemistry values were in normal range in patients, 
serum controls (n=82) and in six liver donors. Donor liver biopsies showed normal histology 
(n=5) or mild steatosis (n=1). None of patients or controls had medications affecting 
cholesterol metabolism (e.g statins) or composition of bile (e.g ursodeoxycholic acid).  
Baseline characteristics of patients with CS and PS are outlined in Table 1. Iso-BMI and serum 
total cholesterol and LDL cholesterol levels were significantly higher in CS-patients when 
compared to PS-patients The frequency of histologic alterations in liver were comparable in both 
groups.  
No surgical complications occurred during cholecystectomy and liver biopsy. Before 
cholecystectomy four patients (CS n=2, PS n=2) underwent endoscopic sphincterotomy for 
removal of common bile duct stones. All patients were discharged by the third postoperative day. 
At outpatient clinic 1-2 months postoperatively all had normal abdominal ultrasonography and 
plasma liver biochemistry values (data not shown). 
Predisposing conditions for gallstones 
Twenty-one (66%) patients had underlying conditions that potentially predispose to  gallstone 
disease (16-18). Overall, predisposing conditions occurred equally often in CS patients (10/15) 
and PS patients (11/17; p = 0.99) and in male (8/13) and female (13/19; p = 0.72) gallstones 
patients. Apart from obesity, 5/15 (33%) CS-patients and 11/17 (65%) PS-patients had any other 
predisposing conditions (p=0.16), which are detailed in a separate table (Suppl Table 1, 
Supplemental Digital Content, http://links.lww.com/MPG/B642). Three PS-patients had an 
associated intestinal disorder including Crohn’s disease, necrotizing enterocolitis and 
gastroschisis. 
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Gallstone cholesterol and non-cholesterol sterols 
Median stone weight of CS and PS was 57 mg (26-136) and 22 mg (14-41), respectively (p = 
0.04). Cholesterol concentration (% of weight) was 85% (76-89) in CS and 0.6% (range 0.3-1.8) 
in PS (p = 0.0003). Total plant sterol concentrations (% of weight) were 14% (8.6-15) in CS and 
0.3% (0.1-0.6) in PS (p<0.001). All PS were classified as black PS. 
Cholesterol precursor (cholestenol. lathosterol and desmosterol), cholestanol and plant sterol 
(campesterol, sitosterol, stigmasterol and avenasterol) ratios to cholesterol are given in. 
Cholesterol precursors to cholesterol ratios were markedly lower and those of plant sterols 
sitosterol, avenasterol and stigmasterol markedly higher in PS compared to CS, while cholestanol 
ratios were similar between the groups. (Suppl Table 2, Supplemental Digital Content, 
http://links.lww.com/MPG/B642). 
Gallstone bile acids 
Total bile acid concentration (% of weight) was 1.6% (0.4-3.0) in CS and 9.5% (3.6-11) in PS, 
(p=0.01) Absolute total concentration of bile acids was ∼7.0 times higher in PS than in CS (Table 
3). The increase was most striking for the primary bile acids, chenodeoxycholic acid and cholic 
acid. PS chenodeoxycholic acid concentration was ∼12 fold higher when compared to CS (Suppl 
Table 3, Supplemental Digital Content, http://links.lww.com/MPG/B642). In PS-patients 
gallstone bile acid concentration correlated with total plant sterols to cholesterol ratio (R2 = 0.83, 
p<0.0001) and cholesterol concentration (R2=0.48, p=0.003).  
Serum cholesterol precursors and plant sterols 
Results of serum cholesterol precursors, cholestanol, and plant sterols are shown in Table 2. 
Compared to both control subjects and PS-patients, patients with CS had significantly higher 
serum cholestenol and lathosterol ratios to cholesterol and significantly lower ratios of plant 
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sterols and cholestanol. Lathosterol/sitosterol and lathosterol/cholestanol ratios were ∼3-5 times 
higher in CS than in PS or controls (p<0.001). Only CS-patients showed decreased 
campesterol/cholestanol ratio when compared to controls. 
In patients with CS there was a positive correlation between serum and gallstone cholesterol 
precursors and plant sterols ratios to cholesterol (R2 = 0.50, p = 0.005 and R2 = 0.97, p < 0.0001, 
respectively). In patients with PS no such correlations were observed (R2 = 0.15, p = 0.16) and 
R2 = 0.12, p = 0.19) suggesting that cholesterol homeostasis was perturbed. 
RNA expression  
The results of RNA expression analyses are outlined in Figures 1 and 2. Among all gallstone 
patients RNA expression of LXR was ∼1.4 times higher than in controls (p=0.06), but the 
difference reached statistical significance only for PS-patients (p = 0.048) (Suppl Figure 1, 
Supplemental Digital Content, http://links.lww.com/MPG/B642). RNA expression of ABCG5 
was ∼2.5 times (p = 0.001) and that of ABCG8 ∼1.8 times higher in all gallstone patients than in 
controls (p = 0.01), and these increases were similar between CS- and PS-patients  
Liver RNA expression of bile acid transporter ABCB11 was ∼1.5 times higher in PS-patients 
compared to CS-patients (p = 0.04), although the difference in relation controls remained 
statistically insignificant (Supplemental Digital Content, http://links.lww.com/MPG/B642). In 
patients with PS, ABCG5expression correlated positively with expression of ACBC11 (R2 = 
0.27, p = 0.03). No meaningful differences in RNA expression of FXR, bilirubin transporter 
ABCC2 and phospholipid transporter ABCB4 were observed between groups (data not shown). 
Liver RNA expression of any of the studied bile transporters did not correlate with age, gender, 
liver steatosis, plasma liver biochemistry values or sterol levels in serum and gallstones either in 
patients or controls. 
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Discussion 
The main new findings of the present study showed that liver RNA expression of sterol 
transporter ABCG5/G8 is similarly increased in children with CS and PS. In addition, ABCG5 
expression associated with activated expression of bile acid transporter ABCB11 and markedly 
higher gallstone primary bile acid concentration in PS when compared to CS. Finally, liver RNA 
expression of bilirubin transporter ABCC2, phospholipid transporter ABCB4 were unaltered in 
both gallstone subgroups. Our measurements of serum surrogate markers of cholesterol 
absorption indicated that CS-patients had low intestinal absorption of cholesterol, while PS-
patients exhibited similar cholesterol absorption to control subjects. Overall synthesis of these 
findings implicate that upregulation of ABCG5/G8 is the primary event in formation of CS, 
resulting in both decreased intestinal absorption and increased biliary secretion of cholesterol 
leading to formation of CS composed mostly of cholesterol. In PS, activation of ABC11 
expression and biliary secretion of bile acids may trigger selective upregulation of ABCG5/G8 in 
the liver (23), enriching PS with primary bile acids and plant sterols relative to cholesterol. 
Low intestinal cholesterol absorption as assessed by serum plant sterols associates with 
formation of CS in both children and adults (8, 12). Individuals who develop gallstones in 
adulthood, display the metabolic trait of low cholesterol absorption already decades earlier in 
childhood, suggesting that low cholesterol absorption is the primary, possibly genetic attribute, 
which leads to increased cholesterol synthesis as in our CS-patients (8, 24). Indeed, 
polymorphism of ABCG8 gene associates with the metabolic trait of low surrogate sterol 
markers of cholesterol absorption in childhood, although presence of the risk allele 19H does not 
explain formation of gallstones alone (12, 25). Our findings extend previous observations by 
showing that of the various canalicular bile transporters studied, only expression of sterol 
transporter ABCG5/G8 was upregulated in children with CS. Notably, phospholipid transporter 
ABCB4 expression was unaltered in accordance with an earlier study showing an association 
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between ABCB4 mutations and low phospholipid cholelithiasis syndrome but not with idiopathic 
pediatric CS (26). Although we did not measure sterol transporter RNA expression in 
enterocytes, the simultaneously low surrogate markers of cholesterol absorption indicates 
enhanced ABCG5/G8 function also in the intestine (27). These findings support the primary role 
of activated ABCG5/G8 in driving biliary cholesterol hypersecretion in the pathogenesis of 
pediatric CS.  
PS are thought to arise from biliary hypersecretion of bilirubin with contributions from the 
enterohepatic circulation of bile acids (11, 28). Malabsorbed bile acids may facilitate intestinal 
absorption and recirculation of unconjugated bilirubin, while high biliary bile acid concentration 
at the expense of cholesterol and phospholipids may cause detergent injury to gallbladder 
mucosa and thereby facilitate gallstone formation (11). Cholestanol is a sensitive biomarker of 
decreased bile flow and elevated serum cholestanol concentration in PS patients suggests an 
association between bile stasis and formation of PS ( 29, 30). While three of our PS-patients had 
an underlying hemolytic disease, we did not observe elevated mean expression of canalicular 
bilirubin transporter ABCC2 and all had normal serum bilirubin at the time of the study. Instead, 
expression of sterol transporter ABCG5/8 and its upstream nuclear receptor regulator LXR were 
significantly increased in patients with PS. Moreover, we noted upregulation of canalicular bile 
acid transporter ACBC11 and 12 to 5 fold higher gallstone primary bile acid concentration in PS 
compared to CS. Similarly to our previous study, the mostly enriched bile acid in PS was a 
primary bile acid chenodeoxycholic acid (8). Moreover, we found positive correlations between 
liver bile acid transporter ACBC11 and sterol transporter ABCG5 expression, and between 
gallstone bile acids and plant sterols, implicating that biliary secretion of bile acids and plant 
sterols were linked with each other in patients with PS.  Interestingly, bile acids, and especially 
chenodeoxycholic acid, increase ABCG5 expression in cultured human hepatocytes (23). 
Together these data indicate that bile acids may have a dual role in formation of PS by causing 
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detergent mucosal injury in increased gallbladder concentrations, and by activating ABCG5 
expression and biliary secretion of sterols. In patients with PS, relatively more plant sterols 
accumulated into gallstones over cholesterol putatively due to its lower hepatic clearance rate 
and limited availability as reflected by the low serum cholesterol concentration (31). 
Unexpectedly, the surrogate sterol markers of cholesterol synthesis in patients with PS were not 
increased above control levels as in our previous study including 35% of PS-patients with 
underlying intestinal absorption defects (12). The normal median level of cholesterol synthesis 
surrogates indicates that most PS-patients in the current study had intact enterohepatic circulation 
of bile acids in addition to normal cholesterol absorption as assessed by serum sterol surrogates. 
Thus, activation of biliary bile acid secretion may also occur in the absence of significant bile 
acid malabsorption and still contribute to PS formation. Indeed, only three (18%) of our 17 PS-
patients had an underlying intestinal disease predisposing to bile acid malabsorption.   
The main limitations of this study includes small number of patients and control donor liver 
biopsies for RNA expression measurements. In addition, different control subject cohorts were 
used for measurements of RNA expression and serum sterol surrogates, and the age of patients 
and controls were not statistically comparable, although both the patients and serum controls 
belonged to pediatric population. Decreased serum campesterol / cholestanol ratio, in general 
suggesting low dietary intake of plant sterols, is conceivably not a valid biomarker in CS - 
patients because campesterol and cholestanol levels are low in these patients because of 
decreased cholesterol absorption efficiency. Finally, we did not include Niemann-Pick C1- like 1 
transporter in our expression studies, although it seems to have a minor role in the 
pathophysiology of gallstone disease (25). However, by combining expression of liver bile 
transporters with surrogates of cholesterol metabolism and bile acid profile in gallstones, this 
study provides novel information on pathogenesis of pediatric gallstone disease.  
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Figure legends 
Figure 1. Liver RNA expression among all gallstone patients (ALL, n=32), patients with 
cholesterol stones (CS, n=15), patients with pigment stones (PS, n=17) and controls (n=6) for (a) 
LXR, (b) ABCG5, and (c) ABCG8. Data are fold changes (mean with 95% confidence interval) in 
relation to controls. *p < 0.05 vs controls **p<0.05 vs PS (Mann-Whitney U test). 
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Figure 2. Liver RNA expression among all gallstone patients (ALL, n=32), patients with 
cholesterol stones (CS, n=15), patients with pigment stones (PS, n=17) and controls (n=6) for 
(a) FXR, (b) ABCB4, and (c) ABCB11. Data are fold changes (mean with 95% confidence 
interval) in relation to controls. *p < 0.05 vs controls **p<0.05 vs PS (Mann-Whitney U test). 
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Table 1. Patient demographics, serum lipids and liver biochemistries and liver and gallbladder 
histology in patients with cholesterol and pigments stones. 
 All patients Cholesterol stones Pigment stones  
 (n=32) (n=15) (n=17) p* 
Age, y 13 (10–16) 15 (12–16) 12 (8–15) 0.08
Females, n (%) 19 (59) 10 (67) 9 (53) 0.49
Iso-BMI, kg/m2 23 (19–27) 27 (19–31) 21 (19 – 23) 0.03
Cholesterol, mmol/l 3.6 (3.2–4.2) 4.0 (3.5–4.5) 2.9 (2.5–3.7) 0.04
HDL, mmol/l 1.3 (1.0–1.5) 1.3 (1.3–1.7) 1.2 (0.8–1.3) 0.96
LDL, mmol/l  2.0 (1.6–2.5) 2.3 (1.9–2.6) 1.6 (1.3–2.2) 0.02
Triglycerides, mmol/l 1.0 (0.6–1.3) 0.6 (0.4–1.3) 1.0 (0.8–1.0) 0.85
Alanine aminotransferase, U/l 28 (23–31) 24 (22–30) 28 (25–30) 0.32
Aspartate aminotransferase, U/l 19 (16–30) 18 (16–19) 18(13–23) 0.29
Alkaline phosphatase, U/l 194 (96–251) 228 (75–269) 205 (137–247) 0.71
Bilirubin (µmol/l)  8.0 (5.0–9.5) 5.0 (5.0–7.0) 9.0 (7.0–11) 0.12
Glutamyl transferase, U/l  18 (13–28  18 (13–22) 24 (13–27) 0.21
Bile acids, µmol/l  5.0 (3.2–8.5) 3.9 (2.7–12) 4.1 (2.3–7.2) 0.40
Prealbumin, mg/l  216 (189–257) 232 (199–242) 205 (169–268) 0.39
Predisposing condition, n (%) 14 (44) 5 (33) 9 (53) 0.31
Liver histology     
Abnormal, n (%) 12 (38) 6 (40) 6 (35) 0.99
Steatosis 7 (22) 5 2  
Steatohepatitis 1 (3) 0 1  
Fibrosis 1 (3) 1 1  
Intracellular cholestasis 
Portal inflammation 
2 (6) 
1(3) 
0 
0 
2 
1 
 
Gallbladder histology      
Abnormal, n (%) 27 (84) 15 (100) 12 (71) 0.05
Chronic cholecystitis 
Acute cholecystitis 
25 (78) 
1(3) 
14 
0 
11 
1 
 
Cholesterolosis 1 (3) 1 0  
Data are medians (interquartile range). *p-values refer to Mann Whitney U test between patients with 
cholesterol and pigment stones. 
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Table 2. Comparison of serum cholesterol and non-cholesterol sterols between patients 
with cholesterol or pigment stones and controls.  
 
Data are medians (interquartile range). Cholesterol mg/dl, non-cholesterol sterols 100 x μg/mg 
of cholesterol. *p-values refer to Kruskall Wallis test among the three groups. ap < 0.05 
compared to controls, bp < 0.05 compared to PS patients by subsequent Mann Whitney U test. 
 Cholesterol stones (n=15 Pigment stones (n=17 Controls (n=82) p* 
Cholesterol 159 (142 – 166) b 134 (104-167) 140 (124–162) 0.07 
Precursors     
Cholestenol 23 (16–28)a,b 12 (10–20) 15 (11–18) 0.02 
Lathosterol 163 (116–198)a,b 82 (59–98) 80 (57–106) 0.002 
Desmosterol 96 (75–121) 88 (71–111) 86 (75–94) 0.42 
Cholestanol       125 (106–149)a,b    178 (169–2241)a  162 (143–185) <0.0001
Plant sterols     
Campesterol 152 (102–194)a,b 286 (218–437) 304 (220–356) 0.0001 
Sitosterol 61 (59–117)a,b 176 (120–210) 163 (134–208) <0.0001
Avenasterol 34 (26–38)a 40 (33–52) 46 (36–53) 0.01 
Stigmasterol 11 (7–17)a 17 (12–19)a 27 (23–34) <0.0001
Lathosterol/Sitosterol 2.0 (0.9–2.6)a,b   0.5 (0.4 –0.7) 0.4 (0.3–0.8) < 0.001
Lathosterol/Cholestanol 1.3 (0.9 – 1.7)a,b  0.4 (0.3 – 0.5) 0.5 (0.3 – 0.7) 0.001 
Campesterol/Cholestanol 1.2 (0.8 – 1.5)a 1.4 (1.3 – 2.1)  1.8 (1.4 – 2.1) 0.003 
